Ozempic and GLP-1 Drug Injury Intake: How to Qualify Pharmaceutical Liability Cases on the First Call

Law firms with personal injury and mass tort practices are watching a new wave of pharmaceutical litigation crash into their intake lines. GLP-1 receptor agonist drugs — Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity — generated billions in prescriptions starting in 2021. The injury claims followed.

As of mid-2026, thousands of lawsuits have been filed across federal MDL courts alleging gastroparesis, stomach paralysis, bowel obstruction, and other serious gastrointestinal injuries tied to GLP-1 use. If your front desk is not ready to qualify these callers, you are sending cases out the door before the call ends.

This is not speculative. The science is settled enough for significant litigation, major plaintiff firms are already in the space, and your potential clients are being told by their doctors and by targeted advertising that they may have a claim. They are calling. The question is whether whoever picks up the phone knows what to do next.

Why GLP-1 Drug Injury Cases Are Flooding Intake Lines Right Now

The GLP-1 receptor agonist class was originally developed for Type 2 diabetes management and later approved for chronic weight management. The weight-loss prescriptions exploded between 2022 and 2025. So did the adverse event reports.

The FDA’s adverse event database shows thousands of reports of severe gastroparesis tied to GLP-1 use. Gastroparesis is a condition where the stomach stops moving food normally, leading to persistent nausea, vomiting, inability to eat, and in serious cases, hospitalization and long-term disability. Patients report months of suffering, significant weight loss from not being able to keep food down, and in some cases, permanent damage requiring gastric feeding tubes.

The litigation is consolidating in federal MDL courts. Settlement discussions are ongoing for some defendants, but thousands of cases remain unresolved and new plaintiffs are still being signed daily.

What this means for your intake operation: callers are coming in from every direction. Some have seen ads. Some were referred by their treating physician. Some read news coverage. Some found you through search. Many do not know they have a legal claim at all. They just know they are sick and something feels wrong.

The caller who says “I was on Ozempic and ended up in the hospital” is not just reporting a bad drug experience. They may be calling about a seven-figure case. Your intake process determines whether you capture it or whether it walks out the door to the next firm on the list.

The 8 Questions That Qualify a GLP-1 Drug Injury Case

These are the questions whoever picks up the phone needs to ask, in this order. Work through them conversationally, not as a checklist. A caller who feels interrogated will hang up.

1. Which drug did you take?
Qualify the drug first. The current litigation focuses on GLP-1 receptor agonists. The primary qualifying drugs include: Ozempic (semaglutide injection), Wegovy (semaglutide, higher dose for weight loss), Mounjaro (tirzepatide), Zepbound (tirzepatide for weight loss), Trulicity (dulaglutide), Victoza (liraglutide), Byetta (exenatide), and Rybelsus (oral semaglutide).

If the caller took a different weight loss drug that is not a GLP-1 agonist, such as phentermine or topiramate, you have a different analysis entirely. Confirm the specific drug name. Ask the caller to check medication packaging or pharmacy records if they are unsure.

2. How long did you take it?
Duration matters for causation arguments. Cases with stronger merit typically involve sustained use over multiple months to a year or more. A caller who took one injection and stopped is a harder case to develop. Document the start date if they know it, and confirm whether they are still taking the drug or stopped.

3. What symptoms did you experience?
The qualifying injury cluster for the current litigation is gastrointestinal. Listen for:

• Nausea that did not resolve after the first few weeks (early nausea is a common, labeled side effect and typically not actionable on its own)
• Persistent vomiting or inability to keep food down
• Abdominal pain or bloating that worsened over time
• A diagnosis of gastroparesis, gastric motility disorder, or stomach paralysis
• Bowel obstruction or intestinal ileus
• Significant unintended weight loss from inability to eat
• Hospitalization for any of the above

Non-GI complaints such as joint pain, fatigue, or mood changes may be real side effects but are generally not the core of the current litigation landscape. Do not disqualify a caller based on secondary complaints, but focus your qualification effort on the GI injury picture.

4. Did a doctor diagnose you with a specific condition?
A formal diagnosis of gastroparesis or a related condition significantly strengthens the case. Imaging studies such as gastric emptying scans, endoscopy findings, and hospitalization records are the documentation backbone for these claims.

Ask: “Did any doctor specifically tell you what was wrong?” If the answer includes gastroparesis or gastric motility disorder, document it immediately. If the caller says “They said my stomach stopped working,” that is likely the same condition described in layman’s terms. Follow up by asking them to request the formal diagnosis name from their records.

5. Were you hospitalized?
Hospitalization is a strong case indicator. It demonstrates severity, creates a paper trail, and establishes the damages picture. Ask:

• How many times were you hospitalized?
• How long was each stay?
• What treatment did they provide?

A caller who was hospitalized twice for uncontrollable vomiting is a fundamentally different case than one who managed symptoms at home. Document both, but flag the hospitalized caller for priority follow-up.

6. Are you still treating?
Cases with ongoing treatment carry higher damages. A caller who still requires medication management, has a gastric feeding tube, or continues to experience symptoms has an evolving damages picture. Note whether the caller is still seeing a gastroenterologist or other specialist.

7. Did you take the drug for weight loss, diabetes management, or both?
The weight-loss indication creates a different liability analysis than the diabetes indication in some cases. Document the indication. Diabetic patients who developed gastroparesis on GLP-1 therapy are also part of the current litigation. Do not disqualify diabetic patients.

8. Do you have the prescribing doctor’s name and the pharmacy you used?
This is for records retrieval, not interrogation. Note the information if the caller offers it. You will need it to pull pharmacy records, which confirm the drug, the dose, and the duration of use.

How to Handle the Caller Who Does Not Know They Have a Case

A significant share of your GLP-1 callers will not open with “I think I have a lawsuit.” They will say things like:

• “I was on Ozempic and ended up in the hospital three times.”
• “My doctor told me I have gastroparesis and I am wondering if the drug caused it.”
• “I saw an ad about Ozempic lawsuits but I am not sure if my situation qualifies.”
• “I stopped taking Wegovy but I am still sick and I do not know what to do.”

These callers need a brief orienting statement before you start the qualification questions. Something like:

“A lot of people who took GLP-1 drugs like Ozempic and Wegovy have reported serious stomach and digestive problems. Our attorneys have been looking at these cases. Can I ask you a few questions to see if your situation might qualify?”

This normalizes their experience and gives you permission to proceed with the qualification script without the caller feeling put on the spot. The caller who says “I do not know if I qualify” is not a weak case. They are a case you have not evaluated yet.

Injury Types That Qualify (and the Ones That Do Not)

Not every GLP-1 user with side effects has a viable case. Knowing the difference saves everyone time and protects your credibility with clients you do sign.

High-value qualification signals:

• Gastroparesis diagnosis confirmed by imaging, such as a gastric emptying scan
• Hospitalization for nausea, vomiting, or inability to eat
• Bowel obstruction requiring surgical intervention or extended hospitalization
• Ongoing inability to maintain normal nutrition or body weight
• Permanent or long-term injury with documented medical records
• Cases involving multiple hospitalizations over time

Factors that weaken or disqualify a case:

• Symptoms limited to the first four to eight weeks of use only, with resolution after stopping
• No medical treatment sought, managed with dietary changes at home
• Full recovery within weeks of stopping the drug, no ongoing issues
• Symptoms that predate GLP-1 use, suggesting a pre-existing condition
• No documentation at all, no doctor visits, no pharmacy records, no diagnosis

A caller with mild early nausea who stopped the drug and recovered fully is not a case today. A caller who took Wegovy for 14 months, was hospitalized twice for vomiting and dehydration, and now carries a permanent gastroparesis diagnosis is your case. The intake process is how you tell the difference.

For a broader view of how to handle pharmaceutical liability intake across multiple drug classes, see our guide to drug injury intake for law firms.

Documentation and Records: What to Collect After Qualification

Once a caller passes your qualification threshold, the records collection process starts. Do not wait until the retainer is signed to begin thinking about documentation. The callers who convert fastest are the ones who understand exactly what they need to gather before the second call.

Tell the caller before the call ends:

• Get the name and contact information for every doctor who treated the GLP-1 related symptoms
• Request a copy of any gastric emptying scan, endoscopy, or imaging study results
• Pull pharmacy records showing the drug name, dosage, and fill dates (most pharmacies can provide this in one visit or online)
• Gather any hospital discharge summaries from related admissions

When you send the follow-up email after the call, include a one-page records checklist. Callers who have a clear action step are more likely to return the call and more likely to convert. Callers who are told “we will be in touch” often are not.

For HIPAA-compliant records authorization language your intake team should use, see the law firm intake HIPAA compliance guide.

Retention vs. Referral: Making the Right Call for Your Firm

Know your capacity before you start signing GLP-1 cases. Mass tort pharmaceutical litigation requires infrastructure that general PI firms may not have in place: MDL co-counsel relationships, high-volume records retrieval systems, funding connections for case costs, and the ability to manage a large docket of similar cases simultaneously.

If your firm does not have this infrastructure, the right move is a referral arrangement with a firm that does, not signing cases you cannot properly service. A well-structured referral earns you a fee without the overhead. A case you sign and cannot manage earns you a bar complaint.

If you are referring out:

• Execute a co-counsel or referral agreement before the case leaves your intake system
• Keep a complete copy of your intake notes
• Log the referral in your case management system with the receiving firm’s details
• Follow up at 30 and 60 days to confirm the case was received and retained

If you are retaining GLP-1 cases directly:

• Get HIPAA-compliant records authorization signed at the point of retainer
• Submit records requests within 48 hours of signing
• Connect the client with pre-settlement funding options if their ongoing medical costs are significant
• Build a case management workflow specifically for mass tort pharmaceutical cases, separate from your general PI docket

How Real-Time Intake Coaching Prevents Missed Cases

The GLP-1 qualification script has eight moving parts. For whoever is picking up the phone, that is a lot to hold in working memory during a live call, especially when the caller is emotional about their health situation.

What eNZeTi’s real-time intake coaching delivers is an active prompt during the call itself, not a reminder to check the script after the fact. When a caller mentions Ozempic or stomach paralysis, the system recognizes the trigger and prompts the intake person with the next question in sequence. The conversation stays on track without the intake person having to track it manually.

The average law firm reviews fewer than 6% of intake calls. The other 94% go unreviewed. In a high-value pharmaceutical intake scenario, one missed question can result in a viable case being wrongly disqualified, or a qualified caller receiving a vague follow-up that never converts to a signed client. Real-time coaching is the system that closes that gap.

Firms using real-time coaching on GLP-1 intake calls are capturing qualification data consistently across every call, regardless of who is on the phone that day. The result is fewer missed signals and a higher rate of qualified callers moving to retainer.

For more on how AI coaching changes the intake performance equation, see how real-time AI coaching differs from post-call analytics.

The Follow-Up Protocol: What to Do After the Call

Pharmaceutical injury callers often need more than one touch before they become a signed client. They want to understand whether their case is worth pursuing, what the process looks like, how long it will take, and whether they have to pay anything upfront. Your follow-up system answers those questions before doubt sets in.

A basic GLP-1 intake follow-up protocol:

1. Same-day callback if the caller did not reach an attorney or case evaluator
2. Email within two hours of the call with a brief summary of next steps and the records checklist
3. Second-touch follow-up call at 48 hours if the caller has not signed or responded
4. Third-touch at seven days with a soft urgency frame: “We want to make sure your records are documented before any filing deadlines in your jurisdiction close.”

The seven-day follow-up is the one most firms skip and the one that converts the most hesitant callers. A caller who did not sign in the first 48 hours is not a lost case. They are a case that needs one more clear reason to move forward.

What to Do This Week

If GLP-1 drug injury calls are arriving at your intake line, and they are, here is what to act on now:

1. Brief whoever picks up the phone today. Print the 8-question qualification sequence above. Walk through one mock call before the day starts. Every person who answers your intake line should know the drug names and the core injury cluster.
2. Audit your last 30 days of calls. How many callers mentioned Ozempic, Wegovy, Mounjaro, or stomach problems following weight loss medication? Were they qualified and followed up correctly?
3. Decide your retention versus referral position. If you are not staffed for mass tort volume, connect with a referral firm this week. Do not let cases accumulate in your intake system without a clear handling plan.
4. Add a HIPAA authorization to your intake packet specific to medical records and pharmacy records. Make it easy for callers to sign immediately.
5. Book a free call analysis at enzeti.com to see how your intake team is actually handling pharmaceutical injury calls. Not how you think they are handling them. The difference is usually significant.

See how eNZeTi works in a real law firm — Book a Free Call Analysis at enzeti.com.